UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE HEALTH, INC. (Exact name of registrant as specified in its charter) Indiana 35-2145715 (State or other jurisdicti ...

Elevance Health, Inc. (ELV) reported second-quarter 2024 adjusted earnings of $10.12 per share, which outpaced the Zacks Consensus Estimate by 1.3%. The bottom line improved 12% year over year.Operating revenues of $43.2 billion dipped 0.4% year over year. However, the top line beat the consensus mark by 0.5%.The quarterly results were driven by improved product revenues in the CarelonRx business and a significant rise in net investment income. However, the upside was partly offset by a decline in Medicaid ...

财务数据和关键指标变化 - 公司报告了第二季度调整后每股收益10.12美元,同比增长12% [7][19] - 公司维持了全年调整后每股收益至少37.20美元的指引,同比增长12% [8] - 公司的商业业务和个人ACA业务实现了强劲增长,会员人数大幅增加 [9] - 公司的Medicaid业务受到行业动态的影响,投资于CarelonRx的业务转型和能力提升 [8] 各条业务线数据和关键指标变化 - 商业业务继续推进利润率恢复计划,实现了稳健的会员增长 [9] - Medicaid业务在新业务中标和再投标方面表现良好,为未来增长奠定基础 [10] - Medicare Advantage业务的星级评级有所提升,但仍面临一定的监管压力和利润率挑战 [12] - Carelon Services业务实现了强劲的收入和利润增长,外部客户业务拓展良好 [13] - CarelonRx业务进行了一些收购整合,正在投资于基础设施和服务水平提升 [14][15] 各个市场数据和关键指标变化 - 公司在Medicaid重新认定过程中,积极主动联系会员以最大限度地确保他们获得医疗服务 [11] - 公司在蓝十字蓝盾州的Medicaid和商业业务协同效应较强,有助于会员重新加入 [11] 公司战略和发展方向及行业竞争 - 公司正在加速能力和服务的发展,投资高增长机会,优化健康保险业务 [16] - Carelon业务作为公司增长的"飞轮",未来有很大的发展潜力 [16] - 公司正在积极拓展Carelon的外部客户业务,并整合近期的收购资产 [13][36][37][57] - 公司在Medicare Advantage市场保持谨慎和纪律,平衡增长和利润率 [12] 管理层对经营环境和未来前景的评论 - 公司在动态的经营环境中保持了谨慎执行,并充分发挥了多元化业务的优势 [7] - 公司正在与各州政府密切合作,确保Medicaid费率保持精算平衡 [11][31][32] - 公司看好Carelon业务的长期增长潜力,并将其作为公司增长的"飞轮" [13][16][57][58] - 公司对Medicare Advantage市场前景保持谨慎乐观,将继续保持纪律和专注 [12] 其他重要信息 - 公司获得了多项外部认可,包括被评为2024年美国最佳工作场所和最佳公司 [17] - 公司正在大幅投资于人工智能技术,以提升会员、医生和员工的体验,提高运营效率 [94][95] 问答环节重要的提问和回答 问题1 **A.J. Rice 提问** 询问公司是否有加速2025年增长的计划 [27] **Gail Boudreaux 回答** 公司预计2025年各业务线收入都将加速增长,包括商业、Medicare Advantage和Medicaid [28] 问题2 **Nathan Rich 提问** 询问Medicaid业务的费率更新情况和利用率变化 [30][31] **Felicia Norwood 和 Mark Kaye 回答** 公司正与各州政府密切合作,确保Medicaid费率保持精算平衡,同时也在应对会员人群结构性变化带来的利用率上升 [32][33][72][73] 问题3 **Kevin Fischbeck 提问** 询问政府业务的利润率情况 [40] **Mark Kaye 回答** 公司预计Medicaid业务利润率将同比下降,Medicare Advantage利润率将有所改善,但仍低于长期目标区间 [41][50]

Key TakeawaysElevance Health posted adjusted earnings per share (EPS) of $10.12 on revenue of $43.2 billion, beating analysts' expectations.Operating revenue fell year-over-year due to "attrition in Medicaid membership."The company reiterated its full-year adjusted EPS guidance of at least $37.20. Elevance Health (ELV) topped analyst expectations with its second-quarter results, but shares of the health insurance provider fell in intraday trading Wednesday amid declining Medicaid membership. The Indianapoli ...

Loading...Loading...Elevance Health Inc. ELV reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion. The decrease was driven by attrition in Medicaid membership, partially offset by higher premium yields reflecting the medical cost trend and growth in CarelonRx product revenue related to members served.Related: Morgan Stanley Says Elevance Health’s Growth Attributed To Consistent Performance But Undervalued.Premiums fell 3.2% to $35.42 b ...

Elevance Health (ELV) came out with quarterly earnings of $10.12 per share, beating the Zacks Consensus Estimate of $9.99 per share. This compares to earnings of $9.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.30%. A quarter ago, it was expected that this health insurer would post earnings of $10.54 per share when it actually produced earnings of $10.64, delivering a surprise of 0.95%.Over the last four quarters, the c ...

Elevance Health 2Q 2024 Earnings Presentation July 17, 2024 Key Highlights 2Q 2024 Results 1 • Elevance Health second quarter results reflect disciplined execution of our strategic initiatives during a dynamic time for the industry • 2Q 2024 adjusted diluted EPS of $10.12 grew 12% year-over-year • 2Q 2024 adjusted operating gain of $2.8B grew 6% year-over-year 2024 Outlook 2 • Reaffirmed 2024 adjusted diluted EPS guidance of at least $37.20, reflecting growth of 12% year-over-year • Continue to optimize our ...

文章核心观点 - 艾伦健康公司(Elevance Health, Inc.)预计将于2024年7月17日公布第二季度业绩 [1] - 公司第二季度每股收益预计为10美元,同比增长10.6% [2] - 公司第二季度收入预计为430亿美元,同比下降0.9% [2] 公司业务表现 - 公司过去4个季度均超出市场预期,平均超出幅度为2.8% [3] - 公司第二季度收入可能受益于产品收入改善和Carelon及Health Benefits部门的强劲贡献 [6] - 公司商业个人、商业费用型、视力和牙科业务的会员人数增加为第二季度业绩提供了动力 [6][7] - 公司Health Benefits业务可能受益于费率调整和商业费用型会员增长 [8] - Carelon品牌的经营利润有望同比增长14%,得益于Carelon Services和CarelonRx的增长 [9] 成本管控 - 公司费用可能下降,主要受益于较低的福利费用、产品销售成本和利息费用 [10] - 公司Medicare、Medicaid和雇主团体风险型会员人数下降可能影响了第二季度保费收入 [11] 总结 - 产品收入增长、承保纪律、Carelon业务强劲以及费用下降可能抵消了Medicare和Medicaid会员下降的负面影响,导致公司第二季度业绩超预期 [12]

In its upcoming report, Elevance Health (ELV) is predicted by Wall Street analysts to post quarterly earnings of $10 per share, reflecting an increase of 10.6% compared to the same period last year. Revenues are forecasted to be $42.99 billion, representing a year-over-year decrease of 0.9%.Over the last 30 days, there has been an upward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their init ...

The healthcare sector is often considered a defensive play, with healthcare stocks to buy offering stability and growth potential even during economic downturns. The sector’s strength is driven by an aging global population, rising healthcare expenditures, and advancements in medical technology. This combination fuels a constant demand for innovation and care, setting the stage for sustained growth for healthcare stocks. Notably, the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), the largest healthcare ...